|  |
| --- |
| November 28, 2016  Tim Lange  Head of Investor Relations  Phone +49 201 177-3150  tim.lange@evonik.com |
| METEX Contact Partner Antoine Darbois  Company Secretary  METabolic EXplorer SA  Phone +33 473 33 4300  Fax +33 473 33 4301  [adarbois@metabolic-explorer.com](mailto:adarbois@metabolic-explorer.com) |

METabolic EXplorer SA

Biopôle Clermont-Limagne

1 rue Emile Duclaux

63360 Saint-Beauzire

France

Phone +33 473 33 4300

www.metabolic-explorer.com

Management

Dr. Benjamin Gonzalez, Chairman

Antoine Darbois

**Evonik Industries AG**

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

**Supervisory Board**

Dr. Werner Müller, Chairman

**Executive Board**

Dr. Klaus Engel, Chairman

Christian Kullmann, Deputy Chairman

Dr. Ralph Sven Kaufmann

Thomas Wessel

Ute Wolf

Registered Office is Essen

Register Court Essen Local Court

Commercial Registry B 19474

**Evonik to acquire technology from METEX for the fermentative production of methionine**

# Evonik will take over a technology package from METabolic EXplorer (METEX)

# The acquisition will strengthen the Evonik biotechnology platform for amino acids

# The move will also enhance the ability of METEX to commercialize other technologies that it has developed as alternatives to chemical processes

# Further opportunities for cooperation are being explored

Essen/Clermont-Ferrand. Evonik Industries AG of Germany and METabolic EXplorer (METEX) of France have agreed that Evonik will acquire a technology package from METEX to strengthen its biotechnology platform for amino acids, following an agreement signed today in Paris. The package includes METEX’s entire technology portfolio for the fermentative production of methionine, as well as patents, essential bacteria strains, and the inoLa™ brand. METEX considers that this agreement will underscore the relevance of METEX’s alternative technologies and will strengthen its ability to commercialize its other technologies.

The transaction also includes a back license agreement pertaining to certain patents to be transferred to Evonik; this agreement will allow METEX to continue using these patents for activities other than those relating to methionine. Furthermore, the companies intend to explore the possibility of a research and development cooperation agreement on the development of biotechnologically produced amino acids.

The total consideration for the transfer of this technology, including a two-year transfer service agreement, amounts to 45 million euros.

Amino acids produced by fermentation are an important pillar of Evonik’s product portfolio for sustainable animal nutrition. Production process efficiency for Biolys® (lysine), ThreAMINO® (threonine) and TrypAMINO® (tryptophane) has been continuously improved over the past few years, and the portfolio was recently expanded to include ValAMINO® (valine).

“Through its fermentative methionine production process, METEX has demonstrated excellent development work and was able to secure wide-ranging patent protection,” says Dr. Emmanuel Auer, head of Evonik’s Animal Nutrition Business Line. “The acquisition of this technology will expand our technological leadership for amino acids produced both chemically and by fermentation,” he explains.

“We have been able to show that the fermentation process for manufacturing methionine is a potential alternative to familiar manufacturing routes. For all of the company’s stakeholders, this is a validation of our technical leadership. Proceeds from the sale will accelerate our ability to further develop and market our other technologies, such as PDO, MPG, or new high-value-added molecules,” says Benjamin Gonzalez, CEO of METEX. “The technology will be transferred to Evonik immediately after the required approval of Evonik committees. This is expected before mid-December 2016.”

According to Mr. Auer, “METEX has many years of experience in the field of strain development and fermentation technology. We believe the potential exists to develop viable process optimization methods for products manufactured using biotechnology—in animal nutrition and beyond. This acquisition will complement and broaden Evonik’s technology portfolio for important innovation fields.”

As Mr. Gonzalez sees it, “Amino acids are clearly high-value-added products, and we are confident that our expertise will deliver new competitive solutions beyond methionine. Improving processes for key natural products for animal feed is one of our top priorities. We look forward to the possibility of a constructive R&D partnership with Evonik to that effect.”

Founded in 1999 and headquartered in the French town of Clermont-Ferrand, METabolic EXplorer is an industrial biochemistry company specializing in the development of biotechnology production processes for bio-based substances used in a wide variety of everyday products such as textile fibers and feed additives. In the future, METEX will sharpen its focus on developing environmentally safe production processes for the consumer goods industry, thus catering to consumers’ expectations of sustainable production processes.

With more than 60 years of experience in the production of essential amino acids, Evonik offers solutions for efficient and sustainable animal nutrition to customers in more than a hundred countries around the world. By extending its product range beyond amino acids to include innovative feed additives, Evonik plans to contribute even further to the efficiency of animal feed and to create additional value for its customers. Evonik products and services in the area of animal nutrition play a key role globally in healthy and affordable feed production that conserves natural resources and reduces the carbon footprint.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

**About Nutrition & Care**

The Nutrition & Care Segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. The segment employed about 7,000 employees, and generated sales of around €4.9 billion in fiscal 2015.

**About METabolic Explorer**

METabolic EXplorer is a biological chemistry company founded in 1999. Its aim is to harness its biotechnological innovations to contribute to alternative production methods for consumer goods that are safe for the environment and that meet new social expectations of consumers. Based on the tried and tested principle of industrial fermentation, METabolic EXplorer's solutions replace today’s petrochemical processes through the use of a wide range of plant-based raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (textile fibers, plastics, resins, solvents, or feed supplements for animal nutrition and health). METabolic EXplorer, based in Clermont-Ferrand, France, is listed on Euronext in Paris (Compartment C, METEX) and is part of the CAC Small index.

**Disclaimer**

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.